FDA’s Post-Market Pharmacoepidemiologic Study Guidance Is 3 Years Away

FDA told participants at a May 7 workshop that it plans to have draft guidance for conducting post-market pharmacoepidemiologic safety studies ready for review in fiscal 2010, with final guidance to be released a year later